260 related articles for article (PubMed ID: 28280214)
1. Initial Evaluation of an Adenosine A
Sakata M; Ishibashi K; Imai M; Wagatsuma K; Ishii K; Zhou X; de Vries EFJ; Elsinga PH; Ishiwata K; Toyohara J
J Nucl Med; 2017 Sep; 58(9):1464-1470. PubMed ID: 28280214
[No Abstract] [Full Text] [Related]
2. In Vivo Evaluation of
Zhou X; Boellaard R; Ishiwata K; Sakata M; Dierckx RAJO; de Jong JR; Nishiyama S; Ohba H; Tsukada H; de Vries EFJ; Elsinga PH
J Nucl Med; 2017 May; 58(5):762-767. PubMed ID: 28062599
[No Abstract] [Full Text] [Related]
3. Radiation Dosimetry of a Novel Adenosine A
Zhou X; Elsinga PH; Khanapur S; Dierckx RA; de Vries EF; de Jong JR
Mol Imaging Biol; 2017 Apr; 19(2):289-297. PubMed ID: 27539309
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation and Quantification of
Khanapur S; van Waarde A; Dierckx RA; Elsinga PH; Koole MJ
J Nucl Med; 2017 Mar; 58(3):466-472. PubMed ID: 27789720
[TBL] [Abstract][Full Text] [Related]
5. Initial human PET studies of metabotropic glutamate receptor type 1 ligand 11C-ITMM.
Toyohara J; Sakata M; Oda K; Ishii K; Ito K; Hiura M; Fujinaga M; Yamasaki T; Zhang MR; Ishiwata K
J Nucl Med; 2013 Aug; 54(8):1302-7. PubMed ID: 23804329
[TBL] [Abstract][Full Text] [Related]
6. In vivo evaluation of [
Zhou X; Khanapur S; de Jong JR; Willemsen AT; Dierckx RA; Elsinga PH; de Vries EF
J Cereb Blood Flow Metab; 2017 Feb; 37(2):577-589. PubMed ID: 26917190
[TBL] [Abstract][Full Text] [Related]
7. Test-retest reproducibility of cerebral adenosine A
Toyohara J; Sakata M; Wagatsuma K; Tago T; Ishibashi K; Ishii K; Elsinga P; Ishiwata K
Ann Nucl Med; 2022 Jan; 36(1):15-23. PubMed ID: 34564828
[TBL] [Abstract][Full Text] [Related]
8. Occupancy of adenosine A
Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
[TBL] [Abstract][Full Text] [Related]
9. Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeys.
Barret O; Hannestad J; Alagille D; Vala C; Tavares A; Papin C; Morley T; Fowles K; Lee H; Seibyl J; Tytgat D; Laruelle M; Tamagnan G
J Nucl Med; 2014 Oct; 55(10):1712-8. PubMed ID: 25082853
[TBL] [Abstract][Full Text] [Related]
10. First clinical assessment of [
Toyohara J; Sakata M; Ishibashi K; Mossel P; Imai M; Wagatsuma K; Tago T; Imabayashi E; Colabufo NA; Luurtsema G; Ishii K
Ann Nucl Med; 2021 Nov; 35(11):1240-1252. PubMed ID: 34368924
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of distribution of adenosine A2A receptors in normal human brain measured with [11C]TMSX PET.
Mishina M; Ishiwata K; Kimura Y; Naganawa M; Oda K; Kobayashi S; Katayama Y; Ishii K
Synapse; 2007 Sep; 61(9):778-84. PubMed ID: 17568431
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and preclinical evaluation of 2-(2-furanyl)-7-[2-[4-[4-(2-[11C]methoxyethoxy)phenyl]-1-piperazinyl]ethyl]7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine-5-amine ([11C]Preladenant) as a PET tracer for the imaging of cerebral adenosine A2A receptors.
Zhou X; Khanapur S; Huizing AP; Zijlma R; Schepers M; Dierckx RA; van Waarde A; de Vries EF; Elsinga PH
J Med Chem; 2014 Nov; 57(21):9204-10. PubMed ID: 25279444
[TBL] [Abstract][Full Text] [Related]
13.
Koole M; Schmidt ME; Hijzen A; Ravenstijn P; Vandermeulen C; Van Weehaeghe D; Serdons K; Celen S; Bormans G; Ceusters M; Zhang W; Van Nueten L; Kolb H; de Hoon J; Van Laere K
J Nucl Med; 2019 May; 60(5):683-690. PubMed ID: 30262518
[TBL] [Abstract][Full Text] [Related]
14. Dosimetry and efficacy of a tau PET tracer [
Ohnishi A; Akamatsu G; Ikari Y; Nishida H; Shimizu K; Matsumoto K; Aita K; Sasaki M; Yamamoto Y; Yamane T; Senda M
Ann Nucl Med; 2023 Feb; 37(2):108-120. PubMed ID: 36411357
[TBL] [Abstract][Full Text] [Related]
15. Kinetic modeling, test-retest, and dosimetry of 123I-MNI-420 in humans.
Tavares AA; Batis JC; Papin C; Jennings D; Alagille D; Russell DS; Vala C; Lee H; Baldwin RM; Zubal IG; Marek KL; Seibyl JP; Barret O; Tamagnan GD
J Nucl Med; 2013 Oct; 54(10):1760-7. PubMed ID: 23970369
[TBL] [Abstract][Full Text] [Related]
16. Whole-body distribution and brain tumor imaging with (11)C-4DST: a pilot study.
Toyohara J; Nariai T; Sakata M; Oda K; Ishii K; Kawabe T; Irie T; Saga T; Kubota K; Ishiwata K
J Nucl Med; 2011 Aug; 52(8):1322-8. PubMed ID: 21764794
[TBL] [Abstract][Full Text] [Related]
17. Characterization in humans of 18F-MNI-444, a PET radiotracer for brain adenosine 2A receptors.
Barret O; Hannestad J; Vala C; Alagille D; Tavares A; Laruelle M; Jennings D; Marek K; Russell D; Seibyl J; Tamagnan G
J Nucl Med; 2015 Apr; 56(4):586-91. PubMed ID: 25698783
[TBL] [Abstract][Full Text] [Related]
18. Brain and whole-body imaging of nociceptin/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A.
Lohith TG; Zoghbi SS; Morse CL; Araneta MF; Barth VN; Goebl NA; Tauscher JT; Pike VW; Innis RB; Fujita M
J Nucl Med; 2012 Mar; 53(3):385-92. PubMed ID: 22312136
[TBL] [Abstract][Full Text] [Related]
19. Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain.
Van Laere K; Ahmad RU; Hudyana H; Dubois K; Schmidt ME; Celen S; Bormans G; Koole M
J Nucl Med; 2013 Aug; 54(8):1285-93. PubMed ID: 23843566
[TBL] [Abstract][Full Text] [Related]
20. [(11)C]TASP457, a novel PET ligand for histamine H3 receptors in human brain.
Kimura Y; Seki C; Ikoma Y; Ichise M; Kawamura K; Takahata K; Moriguchi S; Nagashima T; Ishii T; Kitamura S; Niwa F; Endo H; Yamada M; Higuchi M; Zhang MR; Suhara T
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1653-63. PubMed ID: 26902370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
